Latest News

Wondering if JFrog at around US$45.25 is priced for its future potential or already reflects high expectations? This article walks through the numbers so you can judge the valuation for yourself. JFrog’s share price recently closed at US$45.25, with returns of 2.6% over 7 days, 4.4% over 30 days, a negative 24.0% year to date, 33.3% over 1 year, 143.7% over 3 years and a negative 7.7% over 5 years, giving a mixed picture for anyone looking at entry or exit points. Recent news coverage has...

Readers hoping to buy ABB India Limited ( NSE:ABB ) for its dividend will need to make their move shortly, as the stock...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

With government bond yields jumping, inflation expectations staying elevated and central banks keeping everyone guessing, it can help to focus on companies that rely on their own financial strength rather than cheap money. That is where a solid balance sheet, high return on equity and a history of sound execution start to matter. The screener used for this article looks for exactly that combination, which can appeal to investors who want quality first. In the sections that follow, you will...

If you are wondering whether SLB at around US$56.15 still offers value or is starting to look stretched, the key is to look past the headline share price and focus on what different valuation methods are saying. Over the short term, the stock has returned 6.6% over 7 days and 8.2% over 30 days, while the year to date return stands at 39.7% and the 1 year return at 67.6%. This may have shifted how investors view both its potential and its risks. Recent coverage has focused on how SLB fits...

Wondering if Opera's recent share price puts it in the bargain bin or the overhyped aisle? This article breaks down what the numbers say about value. At a last close of US$17.23, Opera's share price comes with recent returns of 0.6% over 7 days, 25.6% over 30 days, 21.1% year to date, 16.3% over 1 year, 67.0% over 3 years, and 105.9% over 5 years. These moves sit against a backdrop of ongoing interest in Opera as a software name, with headlines frequently focusing on its role as a browser...

Wondering if Amkor Technology at US$78.10 is priced for perfection or still offers value? This article walks you through what the current market price may be telling you. The stock has recently posted returns of 15.9% over 7 days, 73.0% over 30 days, 82.0% year to date, and 350.3% over 1 year, which can change how investors think about both upside potential and risk. These moves sit against the backdrop of ongoing attention on semiconductor supply chains and packaging capacity, as investors...

Wondering whether Palvella Therapeutics at around US$123.59 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price could mean for you. The stock has seen a 23.2% return year to date and a 386.8% return over the last year, alongside shorter term moves of a 2.7% return over 30 days and a 4.9% decline over the past week. Recent attention on Palvella Therapeutics has centered on how the market is reassessing smaller biotech names...

If you are wondering whether OMRON is priced attractively right now, the recent share performance and a mixed valuation picture make it a stock worth a closer look. The share price closed at ¥5,093, with returns of 1.9% over 7 days, 13.0% over 30 days, 27.5% year to date and 21.5% over 1 year. This compares with declines of 31.8% over 3 years and 33.1% over 5 years. Recent news around OMRON has focused on the company as a key name in Japan's technology sector. This helps frame how investors...

In April 2026, ZenaTech expanded its global drone and SaaS footprint by registering Phoenix Aero in Lviv, Ukraine, and opening new offices in Seoul and London to support manufacturing, counter-UAS testing, and regional commercial, government, and defense operations. This rapid build-out of on-the-ground teams across EMEA and APAC highlights ZenaTech’s intent to become a key provider of AI-driven autonomous drone solutions and recurring software services in multiple high-demand markets. We’ll...

If you are wondering whether Ciena's current share price reflects its true worth, the recent trading history gives you plenty to think about. The stock last closed at US$520.80, with returns of 2.6% over 7 days, 19.0% over 30 days and 111.7% year to date, plus very large returns over 1 year and the past 3 and 5 years. Recent coverage has focused on Ciena as a key player in communications technology, with attention on how its products fit into growing data and network demand. This context has...

Varonis Systems launched Atlas, an all in one AI security solution integrated with its Data Security Platform. Atlas is designed to help enterprises with AI inventory discovery, security testing, data leak prevention, and compliance. The launch adds a new AI focused layer to Varonis Systems' existing data security offering. For investors watching NasdaqGS:VRNS, Atlas lands at a time when AI security is a central concern for many enterprise IT teams. The company’s shares most recently closed...

If you are wondering whether Wintrust Financial at US$147.91 still offers value or is starting to look stretched, the recent share price and fundamentals give you some clear clues to work with. The stock has held up over the last week with a 0.2% decline. The 30 day return sits at 8.0% and the 1 year return at 35.6%, with longer term returns of 128.2% over 3 years and 108.7% over 5 years. Recent coverage has focused on Wintrust Financial as part of broader discussions around US regional...

Why Getty Realty Stock Is Drawing Attention Now Getty Realty (GTY) has been on some investors’ radar after a stretch of positive total returns over the past year, prompting closer scrutiny of its income profile and recent share performance. See our latest analysis for Getty Realty. Getty Realty’s share price has eased slightly in the very short term, with a 1 day share price return of 0.92% decline and a 7 day share price return of 3.35% decline. However, the 90 day share price return of...

Investors in China Telecom Corporation Limited ( HKG:728 ) had a good week, as its shares rose 2.2% to close at HK$5.01...

FDA extends Priority Review for Savara’s molgramostim BLA in autoimmune PAP by three months following a major amendment. Regulator cites no new safety, efficacy, or manufacturing concerns in connection with the extension. Extension reflects ongoing review activity for Savara’s lead product candidate, ticker NasdaqGS:SVRA. Savara, listed on NasdaqGS:SVRA, focuses on therapies for rare respiratory diseases, with molgramostim as its most advanced program targeting autoimmune pulmonary alveolar...

Last week, you might have seen that InnoCare Pharma Limited ( HKG:9969 ) released its first-quarter result to the...

It looks like HRnetGroup Limited ( SGX:CHZ ) is about to go ex-dividend in the next day or two. The ex-dividend date is...

If you are wondering whether CNO Financial Group's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. The stock most recently closed at US$43.71, with returns of 0.2% over 7 days, 7.6% over 30 days, 3.6% year to date, 12.3% over 1 year, 106.9% over 3 years and 90.8% over 5 years. This provides plenty of history to measure current pricing against. Recent coverage around CNO Financial Group has centered on its role...

Vail Resorts (NYSE:MTN) reports that an unusually warm winter and record low snowfall have sharply reduced skier visits across its resorts. The company now expects full year results to come in near the lower end of its previously issued guidance. Weather driven disruption to skier visitation is creating a material headwind for resort revenue and in resort spending. For investors watching Vail Resorts, the operational setback comes on top of a weak share price backdrop. NYSE:MTN closed at...

If you are wondering whether ANI Pharmaceuticals at around US$78.64 is priced attractively or already reflects a lot of optimism, the starting point is to understand what the current share price implies about future expectations. The stock shows mixed recent returns, with a 2.8% decline over 7 days, a 6.2% gain over 30 days, a 0.3% return year to date, 12.6% over 1 year, 108.5% over 3 years and 136.3% over 5 years. Recent coverage around ANI Pharmaceuticals has focused on its position within...

China Resources Power Holdings (SEHK:836) has released operating figures for March and the past 3 months of 2026, highlighting higher total net generation and a larger contribution from photovoltaic assets despite weaker wind conditions. See our latest analysis for China Resources Power Holdings. The recent operating update comes as the share price trades at HK$19.86, with a 7 day share price return of 5.47% and a year to date share price return of 12.65%, alongside a 5 year total shareholder...

If you are wondering whether TransMedics Group at around US$110.93 is still priced attractively or already baking in a lot of optimism, this article walks through the key valuation clues. The stock has had a mixed recent run, with a 4.3% pullback over the last 7 days, an 8.5% gain over 30 days, a 9.6% decline year to date, an 18.6% return over the past year, and a very large 3 year gain of around 40.2%. Recent headlines around TransMedics Group have continued to focus on its position in the...

Innovative Aerosystems has acquired an exclusive perpetual license from Honeywell International (NasdaqGS:HON) for aircraft power generating systems. The transaction covers customer contracts, intellectual property rights, and both OEM and aftermarket assets tied to these systems. This move reshapes how Honeywell participates in aircraft power technologies across commercial and defense programs. For you as an investor, this is a focused portfolio move within Honeywell's aerospace business...